Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Prior treatment

• Prior treatment with a PRMT5 or MAT2A inhibitor therapy.
• Major surgery within 4 weeks of first dose of study treatment.

Other illness

• History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment.
• History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications.
• Cardiac abnormalities.

Other

• Active brain metastases or carcinomatous meningitis.
• Other protocol-defined Inclusion/Exclusion criteria apply.

• Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue.
• Unresectable or metastatic disease.
• Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible.
• Age ≥ 18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Adequate organ function.